

WYOMING MEDICAID

ADDITIONAL THERAPEUTIC CLASSES WITH CLINICAL CRITERIA

Unless otherwise noted, generic substitution is mandatory.
Last Updated 10/10

THERAPEUTIC CLASS	DRUG NAME	CLINICAL CRITERIA
ANTICONVULSANTS	gabapentin	Client must have gabapentin on file in the previous 90 days OR a diagnosis of chronic pain, epilepsy, neuropathic pain, postherpetic neuralgia, vasomotor symptoms due to menopause or vasomotor symptoms due to prostate cancer in the last 12 months.
	lamotrigine	Client must have lamotrigine on file in the previous 90 days OR a diagnosis of epilepsy, bipolar, mood disorder or schizoaffective disorder in the last 12 months.
	levetiracetam	Client must have levetiracetam on file in the previous 90 days OR a diagnosis of epilepsy in the last 12 months.
	LYRICA	Client must have Lyrica on the file in the previous 90 days OR a diagnosis of epilepsy or cancer in the last 12 months. A 6-week trial of amitriptyline OR cyclobenzaprine AND Savella will be required if the client has a diagnosis of fibromyalgia. A trial and failure of gabapentin greater than or equal to 30 days is required if the client has a diagnosis of neuropathic pain associated with diabetes, neuropathies or postherpetic neuralgia in the last 12 months.
	oxcarbazepine	Client must have oxcarbazepine on the file in the previous 90 days OR a diagnosis of epilepsy, bipolar or unspecified mood disorders in the last 12 months.
	topiramate	Client must have topiramate on file in the previous 90 days OR a diagnosis of epilepsy or migraines in the last 12 months.
	zonisamide	Client must have zonisamide on file in the previous 90 days OR a diagnosis of epilepsy in the last 12 months.
	ACNE COMBINATIONS Clindamycin Phosphate-Tretinoin Gel	VELTIN
ZIANA		Client must use separate agents. Acne products are limited to clients ≤ 20 years of age.
BOTOX AGENTS	BOTOX	Client must have diagnosis of cervical dystonia (spasmodic torticollis), strabismus and blepharospasm associated with dystonia, spasmodic dystonia (laryngeal dystonia), spasmodic dysphonia, hand dystonia (writer's, musician's, or typist's cramp), torsion dystonia, tongue dystonia, hand tremor, voice tremor, spasticity associated with cerebral palsy, stroke, multiple sclerosis, chronic anal fissure, achalasia, hyperhidrosis including gustatory sweating (frey's syndrome), piriformis syndrome, hemifacial spasm, sialorrhea, detrusor-sphincter dyssynergia or oromandibular dystonia. The following additional criteria will be required before approval will be given to clients with the diagnosis of primary hyperhidrosis: a 6-month trial and failure of topical dermatologics (ie. Aluminum chloride, tannic acid, glutaraldehyde, anticholinergics), systemic anticholinergics, tranquilizers, or NSAIDS AND prescription strength antiperspirants.
	DYSPORT	Client must have diagnosis of cervical dystonia (spasmodic torticollis).
	MYOBLOC	Client must have diagnosis of cervical dystonia (spasmodic torticollis).
	XEOMIN	Client must have diagnosis of cervical dystonia (spasmodic torticollis) OR diagnosis of blepharospasm and a 30 day trial and failure of Botox.
	FENTANYL (SHORT-ACTING)	
FENTANYL (SHORT-ACTING)	ACTIQ	Client must be ≥ 16 years of age AND have a diagnosis of malignant cancer or received antineoplastic therapy in the last 12 months.
	FENTORA	Client must be ≥ 16 years of age AND have a diagnosis of malignant cancer or received antineoplastic therapy in the last 12 months.
	ONSOLIS	Client must have a diagnosis of breakthrough cancer pain AND a trial and failure of fentanyl transmucosal and buccal tablets greater than or equal to a 14 day supply in the last 12 months.
	SEX HORMONES	
SEX HORMONES	Chorionic Gonadotropin	Client must have a diagnosis of prepubertal cryptorchidism or hypogonadism in the last 12 months.
	leuprolide	Client must have a diagnosis of prostate cancer, endometriosis, uterine leiomyomata or central precocious puberty in the last 12 months.
	NOVAREL	Client must have a diagnosis of prepubertal cryptorchidism or hypogonadism in the last 12 months.
	PLENAXIS	Client must have diagnosis of prostate cancer in the last 12 months.
	SUPPRELIN LA	Client must have diagnosis of prostate cancer or central precocious puberty in the last 12 months
	SYNAREL	Client must have diagnosis of central precocious puberty or endometriosis in the last 12 months.
	TRELSTAR	Client must have diagnosis of prostate cancer in the last 12 months.

WYOMING MEDICAID

ADDITIONAL THERAPEUTIC CLASSES WITH CLINICAL CRITERIA

Unless otherwise noted, generic substitution is mandatory.
Last Updated 10/10

THERAPEUTIC CLASS	DRUG NAME	CLINICAL CRITERIA
SEX HORMONES <i>continued</i>	VANTAS	Client must have diagnosis of prostate cancer or central precocious puberty in the last 12 months.
	ZOLADEX	Client must have diagnosis of prostate cancer, breast cancer, endometrial thinning or endometriosis in the last 12 months.
VACCINES		
	CERVARIX	Approved for clients \geq 19 years of age. Clients < 19 years of age refer to the immunization program at 307-777-7952.
	GARDASIL	Approved for clients \geq 19 years of age. Clients < 19 years of age refer to the immunization program at 307-777-7952.
VERSA FOAM AGENTS		
	clobetasol propionate (foam)	Trial and failure of 2 other dosage forms greater than or equal to a 14 day supply in the last 12 months OR a diagnosis of scalp psoriasis or alopecia areata will be required prior to approval.
	clindamycin (aerosol)	Trial and failure of 2 other dosage forms greater than or equal to a 14 day supply in the last 12 months OR a diagnosis of scalp psoriasis or alopecia areata will be required prior to approval.
	EXTINA	Trial and failure of 2 other dosage forms greater than or equal to a 14 day supply in the last 12 months OR a diagnosis of scalp psoriasis or alopecia areata will be required prior to approval.
	LUXIQ	Trial and failure of 2 other dosage forms greater than or equal to a 14 day supply in the last 12 months OR a diagnosis of scalp psoriasis or alopecia areata will be required prior to approval.
	OLUX-E	Trial and failure of 2 other dosage forms greater than or equal to a 14 day supply in the last 12 months OR a diagnosis of scalp psoriasis or alopecia areata will be required prior to approval.
	SALKERA	Trial and failure of 2 other dosage forms greater than or equal to a 14 day supply in the last 12 months OR a diagnosis of scalp psoriasis or alopecia areata will be required prior to approval.
	VERDES0	Trial and failure of 2 other dosage forms greater than or equal to a 14 day supply in the last 12 months OR a diagnosis of scalp psoriasis or alopecia areata will be required prior to approval.
MISC.		
	alprazolam ODT	Client must use alprazolam.
	AMPYRA	Client must have a diagnosis of a gait disorder associated with Multiple Sclerosis.
	ATOPICLAIR	Approved for children \leq 5 years of age.
	buprenorphine	Buprenorphine will be allowed in pregnancy and nursing. Dosage limits apply. Only one narcotic prescription will be allowed between fills.
	dronabinol	Client must have a diagnosis of AIDS or Cancer. Dosage limits apply.
	ELIPHOS	Trial and failure of Phoslo greater than or equal to a 14 day supply in the last 12 months will be required prior to approval.
	INTUNIV	Client must have a diagnosis of ADHD or ADD. Prior authorization will be required for clients under the age of 5. Client must have a trial and failure of a stimulant greater than or equal to a 14 day supply OR a trial and failure of Strattera greater than or equal to a 30 day supply AND a 14 day trial and benefit of guanfacine (Tenex) in the previous 12 months OR a contraindication to ADHD medications (including stimulant and non-stimulant) OR a TIC disorder associated with stimulants (trial of stimulant required).
	LIDODERM PATCHES	Client must have a diagnosis of peripheral neuropathy or post herpetic neuralgia.
	LYSTEDA	Trial and failure of an oral contraceptive or progesterone only hormone replacement AND one NSAID greater than or equal to a 90 day supply in the last 12 months will be required prior to approval.
	MOXATAG	Client must use amoxicillin.
	MULTAQ	Client must use amiodarone.
	NUVIGIL	Trial and failure of Provigil greater than or equal to a 14 day supply in the last 12 months will be required prior to approval.
	ondansetron	Clients \leq 11 will be allowed a one (1) day supply every 30 days unless they have a diagnosis of cancer. No limits for clients \geq 12.
	ORAVIG	Client must have diagnosis of oral candidiasis AND head/neck cancer or HIV.
	ORBIVAN	Trial and failure of ALL butalbital containing agents, the max dose of acetaminophen, and the max dose of a preferred NSAID. For the treatment of migraine headache, ALL preferred migraine agents must also be tried in addition to the butalbital, APAP, and NSAID trials.
	promethazine	Approved for clients \geq 3 years of age.
PROVIGIL	Client must be \geq 16 years of age. Client must have a diagnosis of narcolepsy, obstructive sleep apnea, shift work sleep disorder or Multiple Sclerosis (MS) Fatigue. Diagnosis of MS will require a fatigue severity scale score of 5.0, a 60 day trial of amantadine AND discontinuation of medications that may contribute to drowsiness or fatigue.	

WYOMING MEDICAID
ADDITIONAL THERAPEUTIC CLASSES WITH CLINICAL CRITERIA

Unless otherwise noted, generic substitution is mandatory.
 Last Updated 10/10

THERAPEUTIC CLASS	DRUG NAME	CLINICAL CRITERIA
MISC. <i>continued</i>	QUALAQUIN	Client must be in plan 190, 191, 192, or 193. Client must have a history of malaria in the past 6 months.
	SOLODYN	Client must use minocycline ER.
	SUBOXONE	Only one narcotic prescription will be allowed between fills. Dosage limits apply. Subutex (<i>buprenorphine</i>) will be allowed in pregnancy and nursing.
	SYNAGIS	Requires prior authorization (PA), which will be accepted November 1 st for the start date of November 15 th . Max of 5 doses per season at a dosing interval greater than or equal to 28 days. Client must meet the following criteria: Chronic Lung Disease: Client is ≤ 24 months of age at start of therapy and has chronic lung disease of prematurity requiring medication or oxygen within 6 months of the start of RSV season. OR Congenital Heart Disease: Client is ≤ 24 months of age at start of therapy and has hemodynamically significant congenital heart disease and one or more of the following: *Is receiving medication to control congestive heart failure *Has a diagnosis of moderate to severe pulmonary hypertension *Has a diagnosis of cyanotic heart disease OR Prematurity: *Client is ≤ 12 months of age at start of RSV season and born at ≤ 28 weeks, 6 days gestational age *Client is ≤ 12 months of age at start of RSV season and born at 34 weeks, 6 days gestational age and has either severe neuromuscular disease or congenital abnormalities, either of which compromise handling of respiratory secretions *Client is ≤ 6 months of age at the start of the RSV season and born between 29weeks, 0 days and 35 weeks, 6 days gestational age
	TEKAMLO	Client must use separate agents
	TRIBENZOR	Client must use separate agents/criteria still applies.
	ULESFIA	Trial and failure of permethrin AND lindane will be required prior to approval.
	ULORIC	Trial and failure of allopurinol greater than or equal to a 90 day supply in the last 12 months will be required prior to approval.
	XERESE	Client must use separate agents.
	XIFAXAN	Xifaxan 200mg - Client must have a diagnosis of traveler's diarrhea. Xifaxan 550mg - Client must be ≥ 18 years of age and have a diagnosis of reduction in risk of overt hepatic encephalopathy recurrence.
XOLAIR	Trial and failure of Salmeterol, Formoterol, Albuterol, Theophylline SR, Singulair, or Accolate AND a trial and failure of Qvar, Pulmicort Turbinaler, Aerobid, Azmacort, or Flovent at maximum doses in the last 30 days will be required prior to approval.	